CenExel is proud to highlight the poster presented at the Annual Meeting of the International Society for CNS Clinical Trials and Methodology Conference, February 2018, Washington,...
CenExel is proud to highlight the poster presented at the Annual CNS Summit Meeting, November 2018, Boca Raton, FL. ABSTRACT Introduction: This investigation is the first known...
In the dynamic realm of clinical drug development, a new star is rising: Ethnic Bridging clinical trials, also known as ethnobridging or Asian bridging...
Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo...
Tampa, Florida, July 26, 2023 /GlobeNewswire/ — CenExel FCR has been named the 2023 Tampa Bay Times People’s Choice, Best of the Best in Clinical...
Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our...
Salt Lake City, May 18, 2023 /GlobeNewswire/ — CenExel announces the addition of Michele Baptista as the new Senior Director of Business Development. In this...
CenExel is proud to highlight the poster we’re presenting at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2023, Miami, FL....
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...
